Eptinezumab

• Description :

  Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines[1][2].

• Product Name Alternative :

  ALD-403

• UNSPSC :

  12352203

• Target :

  CGRP Receptor

• Type :

  Inhibitory Antibodies

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/eptinezumab.html

• Purity :

  99.90

• Solubility :

  H2O

• Smiles :

  [Eptinezumab]

• Molecular Weight :

  (143.36 kDa)

• References & Citations :

  [1]Dhillon S. Eptinezumab: First Approval. Drugs. 2020;80 (7) :733-739.|[2]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD) : National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Eptinezumab. 2021 Jul 9.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Launched

• CAS Number :

  [1644539-04-7]